NEW YORK (360Dx) – Laboratory Corporation of America announced today that its Covance drug development business has signed a licensing agreement with Genfit to use a non-alcoholic steatohepatitis liver diagnostic (NASH) assay in the clinical research market.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.